Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
South Korea · Delayed Price · Currency is KRW 7,280.00
-250.00 (-3.32%)
At close: Apr 8, 2026
Bukwang Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 12,558 | -2,641 | -31,330 | -2,475 | -916.62 |
Depreciation & Amortization | 5,489 | 4,106 | 4,292 | 5,117 | 4,843 |
Loss (Gain) From Sale of Assets | -374.4 | -53.75 | -30.64 | -52.25 | -220.05 |
Asset Writedown & Restructuring Costs | 2,943 | 9,585 | - | - | - |
Loss (Gain) From Sale of Investments | 6,009 | -738.9 | 564.4 | 567.47 | -90.53 |
Loss (Gain) on Equity Investments | -18.33 | -343.13 | 1,501 | -58.57 | 1,361 |
Stock-Based Compensation | 13.2 | -3.53 | 147.49 | 44.33 | 3.41 |
Provision & Write-off of Bad Debts | -22.4 | -554.54 | -4,897 | 2,902 | 1,694 |
Other Operating Activities | 7,454 | 379.98 | -3,373 | 3,261 | 917.18 |
Change in Accounts Receivable | -4,039 | 12,933 | 57,117 | -423.74 | 11,554 |
Change in Inventory | -8,585 | 14,296 | -18,388 | 208.43 | 12,182 |
Change in Accounts Payable | 2,475 | 2,432 | -14,160 | 9,154 | -2,735 |
Change in Other Net Operating Assets | -2,436 | -5,035 | -806.65 | -1,782 | -2,066 |
Operating Cash Flow | 21,464 | 34,362 | -9,362 | 16,461 | 26,525 |
Operating Cash Flow Growth | -37.54% | - | - | -37.94% | 3567.88% |
Capital Expenditures | -7,257 | -1,938 | -2,835 | -4,298 | -785.05 |
Sale of Property, Plant & Equipment | 737.7 | 45.52 | 142.2 | 71.27 | 388.45 |
Divestitures | - | 369.75 | 238.89 | - | - |
Sale (Purchase) of Intangibles | -3,937 | -629.25 | 267.3 | -692.11 | -4.47 |
Investment in Securities | -82,225 | -25,575 | -152.85 | 1,588 | 5,150 |
Other Investing Activities | -3,000 | 0 | 20 | 180 | -0 |
Investing Cash Flow | -95,682 | -27,727 | -2,319 | -3,151 | 4,749 |
Short-Term Debt Issued | - | 10,000 | - | 10,000 | - |
Long-Term Debt Issued | - | - | 80,000 | - | - |
Total Debt Issued | - | 10,000 | 80,000 | 10,000 | - |
Short-Term Debt Repaid | - | -10,000 | - | -10,000 | -20,000 |
Long-Term Debt Repaid | -459.42 | -63,602 | -447.86 | -433.92 | -452.42 |
Total Debt Repaid | -459.42 | -73,602 | -447.86 | -10,434 | -20,452 |
Net Debt Issued (Repaid) | -459.42 | -63,602 | 79,552 | -433.92 | -20,452 |
Issuance of Common Stock | 88,158 | - | - | 100 | - |
Repurchase of Common Stock | - | - | - | - | -516.19 |
Dividends Paid | -4,933 | - | - | -6,845 | -6,225 |
Other Financing Activities | -2,981 | -4,049 | -2,714 | -469.66 | -290.94 |
Financing Cash Flow | 79,784 | -67,651 | 76,839 | -10,398 | -27,485 |
Foreign Exchange Rate Adjustments | 551.43 | -120.02 | 552.82 | -172.98 | -303.37 |
Net Cash Flow | 6,117 | -61,136 | 65,710 | 2,740 | 3,486 |
Free Cash Flow | 14,206 | 32,424 | -12,196 | 12,163 | 25,740 |
Free Cash Flow Growth | -56.18% | - | - | -52.74% | - |
Free Cash Flow Margin | 7.08% | 20.25% | -9.69% | 6.37% | 14.11% |
Free Cash Flow Per Share | 171.96 | 478.75 | -178.17 | 177.69 | 375.98 |
Cash Interest Paid | 2,981 | 4,032 | 1,139 | 147.12 | 290.94 |
Cash Income Tax Paid | -8,442 | 1,588 | 900.4 | 4,116 | 8,933 |
Levered Free Cash Flow | -9,886 | -34,262 | 59,149 | 9,285 | 25,241 |
Unlevered Free Cash Flow | -7,451 | -30,206 | 61,529 | 10,385 | 26,121 |
Change in Working Capital | -12,586 | 24,626 | 23,763 | 7,156 | 18,934 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.